Laurus Labs
Laurus Labs Ltd is an Indian pharmaceutical manufacturing enterprise producing active pharmaceutical ingredients (APIs), finished dosage formulations, and contract development services. The company manufactures APIs for antiretrovirals, hepatitis C, oncology, and cardiovascular therapies, alongside contract manufacturing for global biopharmaceutical companies. Main revenue drivers comprise global commercial sales of active pharmaceutical ingredients, finished drug formulations, and custom synthesis service fees. Laurus Labs serves global pharmaceutical corporations, generic drug marketers, hospital networks, and public health procurement agencies across Asia, North America, Europe, and Africa. The company holds a market-leading position as a major low-cost supplier of antiretroviral APIs and active ingredients. Headquartered in Hyderabad, Telangana, India, it is listed on the National Stock Exchange of India and BSE.
9 of the funds FundTelligence covers report a position in Laurus Labs.
- Legal name
- Laurus Labs Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 9
Funds holding Laurus Labs
- Handelsbanken Asia SMB — Handelsbanken · 1.14 % (full portfolio disclosed, August 2026)
- SEB Emerging Marketsfond — SEB · 0.17 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.09 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets — Storebrand · 0.09 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- DNB Emerging Markets Index — DNB · 0.06 % (full portfolio disclosed, September 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.06 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.